Prostate Cancer Trial, Recruiting NCT07645391 Sponsor: University of Michigan Rogel Cancer Center Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07645391
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 35 and 70 years old
  • People who are able to understand and agree to take part in the trial (give informed consent)
  • People who, if they have another cancer, are expected to live more than 5 years
  • People who carry a known gene change (mutation) linked to prostate cancer, such as BRCA1, BRCA2, Lynch syndrome, or p53
  • People who carry a mutation in a gene suspected to be linked to prostate cancer, such as ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, or HOXB13
  • People who are considered definite carriers of one of the above mutations because a close female relative (such as a sister or daughter) has a confirmed mutation
  • Men who have any family member with one of the above gene mutations
  • People with a family history of breast, prostate, or ovarian cancer in at least 2 relatives, or in 1 relative who was diagnosed before the age of 50

Who may not be able to join:

  • People who are unable to produce any urine (a condition called anuria)
  • People who have already been diagnosed with or treated for prostate cancer
  • People who are not able or willing to provide informed consent
  • People with a life expectancy of less than 5 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Todd M Morgan, MD, University of Michigan Rogel Cancer Center

Phone: 1-800-865-1125

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Michigan Rogel Cancer Center
Registry
ClinicalTrials.gov
Start date
1 January 2017
Est. completion
1 January 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Predictors of any HG PCa

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov